Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Arbaclofen ER in MS Spasticity
NCT03319732Phase 3Completed
- Sponsor
- RVL Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of arbaclofen in spasticity, sponsored by RVL Pharmaceuticals. Started Apr 2018; status: completed.
02
Drugs
arbaclofen
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT03319732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03319732.